



## OPEN ACCESS

## EDITED BY

Jisu Li,  
Brown University, United States

## REVIEWED BY

Xiaonan Zhang,  
University of Canberra, Australia  
Che Colpitts,  
Queen's University, Canada

## \*CORRESPONDENCE

Isabelle Chemin  
✉ isabelle.chemin@inserm.fr

RECEIVED 27 June 2023

ACCEPTED 15 August 2023

PUBLISHED 01 September 2023

## CITATION

Roca Suarez AA, Planel S, Grand X, Couturier C, Tran T, Porcheray F, Becker J, Reynier F, Delgado A, Cascales E, Peyrot L, Tamellini A, Saliou A, Elie C, Baum C, Vuong BQ, Testoni B, Roques P, Zoulim F, Hasan U and Chemin I (2023) Interspecies comparison of the early transcriptomic changes associated with hepatitis B virus exposure in human and macaque immune cell populations. *Front. Cell. Infect. Microbiol.* 13:1248782. doi: 10.3389/fcimb.2023.1248782

## COPYRIGHT

© 2023 Roca Suarez, Planel, Grand, Couturier, Tran, Porcheray, Becker, Reynier, Delgado, Cascales, Peyrot, Tamellini, Saliou, Elie, Baum, Vuong, Testoni, Roques, Zoulim, Hasan and Chemin. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Interspecies comparison of the early transcriptomic changes associated with hepatitis B virus exposure in human and macaque immune cell populations

Armando Andres Roca Suarez<sup>1,2,3</sup>, Séverine Planel<sup>4</sup>, Xavier Grand<sup>1,2,3</sup>, Céline Couturier<sup>4</sup>, Trang Tran<sup>4</sup>, Fabrice Porcheray<sup>4</sup>, Jérémie Becker<sup>4</sup>, Frédéric Reynier<sup>4</sup>, Ana Delgado<sup>4</sup>, Elodie Cascales<sup>4</sup>, Loïc Peyrot<sup>4</sup>, Andrea Tamellini<sup>4</sup>, Adrien Saliou<sup>4</sup>, Céline Elie<sup>4</sup>, Chloé Baum<sup>4</sup>, Bao Quoc Vuong<sup>5,6</sup>, Barbara Testoni<sup>1,2,3</sup>, Pierre Roques<sup>7,8,9</sup>, Fabien Zoulim<sup>1,2,3,10</sup>, Uzma Hasan<sup>1,11</sup> and Isabelle Chemin<sup>1,2,3\*</sup>

<sup>1</sup>INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France, <sup>2</sup>University of Lyon, Université Claude-Bernard (UCBL), Lyon, France, <sup>3</sup>Hepatology Institute of Lyon, Lyon, France, <sup>4</sup>BIOASTER, Institut de Recherche Technologique, Lyon, France, <sup>5</sup>Department of Biology, The City College of New York, New York, NY, United States, <sup>6</sup>The Graduate Center, The City University of New York, New York, NY, United States, <sup>7</sup>CEA, Institut François Jacob, Fontenay-aux-Roses, France, <sup>8</sup>Inserm, U1184, Fontenay-aux-Roses and Université Paris-Saclay, Orsay, France, <sup>9</sup>Institut Pasteur de Guinée, Conakry, Guinea, <sup>10</sup>Department of Hepatology, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France, <sup>11</sup>INSERM U1111, Centre International de Recherche en Infectiologie (CIRI), Lyon, France

**Background and aims:** Hepatitis B virus (HBV) infection affects 300 million individuals worldwide, representing a major factor for the development of hepatic complications. Although existing antivirals are effective in suppressing replication, eradication of HBV is not achieved. Therefore, a multi-faceted approach involving antivirals and immunomodulatory agents is required. Non-human primates are widely used in pre-clinical studies due to their close evolutionary relationship to humans. Nonetheless, it is fundamental to identify the differences in immune response between humans and these models. Thus, we performed a transcriptomic characterization and interspecies comparison of the early immune responses to HBV in human and cynomolgus macaques.

**Methods:** We characterized early transcriptomic changes in human and cynomolgus B cells, T cells, myeloid and plasmacytoid dendritic cells (pDC) exposed to HBV *ex vivo* for 2 hours. Differentially-expressed genes were further compared to the profiles of HBV-infected patients using publicly-available single-cell data.

**Results:** HBV induced a wide variety of transcriptional changes in all cell types, with common genes between species representing only a small proportion. In particular, interferon gamma signaling was repressed in human pDCs. At the

gene level, interferon gamma inducible protein 16 (*IFI16*) was upregulated in macaque pDCs, while downregulated in humans. Moreover, *IFI16* expression in pDCs from chronic HBV-infected patients anti-paralleled serum HBsAg levels.

**Conclusion:** Our characterization of early transcriptomic changes induced by HBV in humans and cynomolgus macaques represents a useful resource for the identification of shared and divergent host responses, as well as potential immune targets against HBV.

#### KEYWORDS

HBV, PBMC, transcriptomics, immune response, macaque

## Introduction

Hepatitis B virus (HBV) infection affects close to 300 million individuals worldwide, representing one of the major etiological factors for the development of cirrhosis and hepatocellular carcinoma (Yuen et al., 2018). At the molecular level, the mechanism behind chronic hepatitis B (CHB) is based on persistence of the viral genome as an episomal structure referred to as covalently closed circular DNA (cccDNA), which remains in the nucleus as a viral reservoir and template for viral replication (Martinez et al., 2021). In addition, HBV sequences can be integrated into the human genome and generate hepatitis B surface antigen (HBsAg) (Zhao et al., 2020). High concentrations of circulating HBsAg are associated with a dysfunctional immune response against HBV via a wide variety of mechanisms, which include the impairment of innate immune cells such as dendritic cells, monocytes, macrophages and natural killer (NK) cells, as well as HBV-specific T and B cells (Op den Brouw et al., 2009; Hong and Bertoletti, 2017; Faure-Dupuy et al., 2018; Tout et al., 2018; Bertoletti and Kennedy, 2019; Maini and Burton, 2019; Iannacone and Guidotti, 2022). These alterations do not exclusively result from the direct action of HBV on a particular cell type but can also stem indirectly from a dysregulated crosstalk between immune populations. For instance, it has been reported that HBsAg induces the generation of immunosuppressive monocytes, which are characterized by the expression of programmed death-ligand 1 (PD-L1) and major histocompatibility complex, class I, E (HLA-E). These HBV-induced monocytes educate

NK cells to secrete higher levels of interleukin 10 (IL-10) and decrease the production of interferon gamma (IFN- $\gamma$ ), resulting in the inhibition of CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Li et al., 2018).

Although nucleos(t)ide analogues are highly efficient at suppressing viral replication, HBV is never fully eliminated (EASL, 2017). Thus, these regimens require indefinite treatment to prevent the virological relapse that usually occurs after treatment discontinuation. This has led to a renewed interest to develop new curative strategies and combinations for HBV. In this context, it is believed that HBV cure will be a multi-layered combination approach of direct-acting antivirals and host-targeting agents in order to boost immune responses (Lim et al., 2023). However, the pre-clinical evaluation of immunomodulatory agents against HBV has been hampered by the lack of suitable *in vivo* models (Ortega-Prieto et al., 2019). Non-human primates, such as macaques, are widely used in virological studies due to their close evolutionary relationship to humans (Estes et al., 2018). Nonetheless, only low-titer or transient HBV replication has been observed in Mauritius cynomolgus macaques (*Macaca fascicularis*) (Dupinay et al., 2013). A similar situation has been reported in rhesus macaques (*Macaca mulatta*), in spite of expressing the human version of the HBV receptor sodium taurocholate co-transporting polypeptide (*hNTCP*) (Burwitz et al., 2017). Interestingly, it has recently been reported that viral clearance in macaques expressing *hNTCP* is mediated by an HBV-specific immune response and that immunosuppression leads to the development of a persistent infection (Biswas et al., 2022). Therefore, it is fundamental to have a solid understanding of the immunological differences between humans and non-human primate model organisms. This would allow not only to have a better grasp of the advantages and limitations of each model, but also the identification of potential targets for future clinical interventions. With this aim, we characterized the early transcriptomic changes and cytokine profiles induced by *ex vivo* exposure to HBV in human and cynomolgus macaque peripheral blood mononuclear cells (PBMCs). Thus, the present work represents a useful resource that allows the identification of shared and divergent transcriptional programs between both species, as well as the gene expression changes associated with each particular immune population of the same organism.

**Abbreviations:** AR, acute recovery; APOBEC3G, apolipoprotein B mRNA editing enzyme catalytic subunit 3G; cccDNA, covalently-closed circular DNA; CHB, chronic hepatitis B; CISH, cytokine inducible SH2-containing protein; CR, chronic recovery; GSEA, gene set enrichment analysis; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IA, immune active; IFI16, interferon gamma inducible protein 16; IFN- $\gamma$ , interferon gamma; IL-10, interleukin 10; IRF2, interferon regulatory factor 2; IT, immune tolerant; MAPK, mitogen-activated protein kinase; mDCs, myeloid dendritic cells; NMI, N-Myc and STAT interactor; NTCP, sodium taurocholate co-transporting polypeptide; PBMCs, peripheral blood mononuclear cells; pDCs, plasmacytoid dendritic cells; SOCS, suppressor of cytokine signaling; TNF- $\alpha$ , tumor necrosis factor alpha.

## Methods

### Blood sample collection and PBMC isolation

Human blood samples ( $n=6$ ) were obtained from the French national blood service (Etablissement Français du Sang, Lyon, France). Mauritius cynomolgus blood samples ( $n=6$ ) were provided by the platforms Bioprim and Cynbiose, in agreement with international guidelines (CITES n°FR1503100944-I). PBMCs were isolated using Ficoll-Paque PLUS (GE Healthcare). Samples were frozen in fetal bovine serum (Sigma Aldrich) supplemented with 10% DMSO (Sigma Aldrich) and stored in liquid nitrogen until the day of the experiments.

### Ex vivo HBV exposure

PBMCs of human or macaque origin were thawed, re-suspended in RPMI-1640 (Thermo Fisher Scientific) and evaluated for cell number and viability. For each condition,  $15 \times 10^6$  PBMCs were incubated for 2h at 37°C with 5% CO<sub>2</sub> in RPMI-1640 culture medium  $\pm$  HBV (genotype D, 100 viral genome equivalents/cell) or mock inoculum, which were produced as previously described (Tout et al., 2018). Supernatants were frozen for subsequent cytokine analyses.

### Cytokine profiling

IL-10, IFN- $\gamma$  and tumor necrosis factor alpha (TNF- $\alpha$ ) were analyzed in supernatants by Luminex array. Species-dedicated kits were used in order to ensure that antibodies did not cross-react. Custom Milliplex Non-Human Primate and Human Cytokine Magnetic Bead Panel (Millipore) were used according to the manufacturer's instructions. All samples were analyzed using a Bio-Plex 200 reader and the Bio-Plex Manager Software (Bio-Rad).

### Cell sorting

PBMCs were stained with the antibody panel (Supplementary Table 1) for 15 min at RT, resuspended in D-PBS and immediately sorted into plasmacytoid dendritic cells (pDCs), myeloid dendritic cells (mDCs), T cells and B cells using a FACS Aria II (BD Biosciences) (Supplementary Table 2, Supplementary Figure 1).

### RNA extraction and bulk RNA sequencing (RNA-seq)

A minimum of 5000 sorted cells per sample were lysed in Trizol (Life Technologies) and RNA was extracted using Phasemaker™ Tubes Complete System (Thermo Fischer Scientific), according to

the manufacturer's instructions. A purification step was added after RNA extraction using the RNA Clean & Concentrator™-5 kit (Zymo Research). The SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Takara Bio) was used for cDNA synthesis, according to the user manual recommendations. Purification of amplified cDNA was performed using the Agencourt AMPure XP kit (Beckman Coulter) and controlled on a 2100 Bioanalyzer using High Sensitivity DNA chips. Following cDNA quantification with the GloMax® Multi-detection system (Promega), all samples were diluted to 30 pg/ $\mu$ L and 150 pg were used for Nextera XT fragmentation according to the Nextera XT protocol. Libraries were diluted to 1 nM and denatured with 0.2 M NaOH at RT for 5 min. Subsequently, 0.2 M Tris-HCl pH 7 was added to ensure that NaOH was fully hydrolyzed in the final solution. Denatured libraries were diluted to 20 pM with pre-chilled hybridization buffer. Paired-end sequencing was performed on a NextSeq 500 sequencer using the NextSeq 500 High Output v2 kit (150 cycles, Illumina).

### Bioinformatics analyses

*Bulk RNA-seq:* Quality of the raw sequences was verified using FastQC. All samples presented a similar profile, with an average Phred quality score above 30. Reads were quantified using the quasi-mapping-based mode of Salmon (Patro et al., 2017). This step needed a preliminary indexing of reference transcripts, which was performed using the "salmon index" command with default setting k-mer size  $k=31$ . The references used were the Genome Reference Consortium Human Build 38 (hg38, Genbank accession GCA\_000001405.15) for the human analysis and Macaca fascicularis\_5.0 (Genbank accession GCA\_000364345.1) for the macaque analysis. Raw counts were processed using the DESeq2 package in R/Bioconductor (Love et al., 2014) (Supplementary Table 3). Pre-ranked gene set enrichment analysis (GSEA) was performed using GenePattern and the gene sets belonging to the Molecular Signatures Database (MSigDB) v7.5.

*Single-cell RNA sequencing (scRNA-seq):* PBMC transcriptomic and clinical data from healthy and HBV-infected patients ( $n=23$ ) was obtained from the Gene Expression Omnibus (GEO) database accession GSE182159 (Zhang et al., 2023). Sample integration was performed using the *FindIntegrationAnchors* and *IntegrateData* functions of Seurat (v4.2) (Satija et al., 2015). Cell clustering was performed with the *FindClusters* function of Seurat using a resolution of 0.5 for the analysis, which resulted in 25 clusters. Marker genes for each of the clusters were identified with the *FindMarkers* function of Seurat and were employed to provide labels to 14 major cell types (Supplementary Figure 2A).

### Statistical analyses

Comparison of cytokine levels in the supernatant of HBV-stimulated and control samples was performed using a Wilcoxon

matched-pairs test. Statistical tests were performed using GraphPad Prism software v9.4 (GraphPad Software).

Differential expression analysis between groups was performed using the Wald test in DESeq2. Gene expression changes were considered significant if presenting a false discovery rate (FDR)  $\leq 0.05$  following correction for multiple testing using the Benjamini-Hochberg method.

## Results

### Short-term *ex vivo* HBV exposure induces transcriptomic changes associated with the immune response in human and macaque PBMC populations

With the aim to perform a comprehensive characterization of the early transcriptomic changes induced by HBV in the peripheral immune compartment, we isolated PBMCs from HBV-negative donors without HBV vaccination ( $n=6$ ) and Mauritian cynomolgus macaques ( $n=6$ ), which were subsequently exposed to HBV *ex vivo* during a two-hour period. PBMCs were then sorted into T cell, B cell, mDC and pDC populations in order to perform bulk RNA-seq (Figure 1A). This allowed us to observe a wide variety of significantly (FDR  $\leq 0.05$ , Wald test) modulated genes induced by HBV exposure in each cell type from both species (Figures 1B, C). The total number of differentially-expressed genes in human and macaque immune populations were: 222 vs 715 in B cells, 617 vs 1058 in T cells, 512 vs 353 in mDCs and 265 vs 592 in pDCs, respectively (Figure 1D). Some of the expression changes common to humans and macaques included the upregulation of suppressor of cytokine signaling 1 (*SOC1*), *SOC2* and cytokine inducible SH2-containing protein (*CISH*) in T cells, which have been described to reflect their activation following antigen stimulation (Yu et al., 2003). In addition, we observed the downregulation of apolipoprotein B mRNA editing enzyme catalytic subunit 3G (*APOBEC3G*) in B and T cells. This is of particular relevance, as *APOBEC3G* has been reported to play a key role during the host immune response against HBV (Turelli et al., 2004). Nonetheless, common genes between both species represented only a small proportion of the total transcriptomic alterations in response to HBV, with the majority of modulated genes being specific to each species (Figure 1D). These results suggest that HBV is able to induce markedly different transcriptional profiles in human and macaque PBMCs early during the host immune response.

### *IFI16* expression is impaired in pDCs exposed to HBV *ex vivo* and persists in HBV-infected patients

In order to gain further insights into the mechanisms leading to this species-specific transcriptomic modulation, we quantified


cytokine levels produced in response to HBV exposure. This allowed us to observe a significant increase ( $p < 0.05$ , Wilcoxon matched-pairs test) in the production of IFN- $\gamma$  and TNF- $\alpha$  in macaque PBMCs exposed to the virus (Figures 2A, B). This stands in contrast to the increased levels of IL-10 in human PBMCs (Figure 2C), suggesting that HBV induces two different cytokine responses, a pro-inflammatory profile in simian and an anti-inflammatory one in humans. In particular, pathway analysis of the human pDC population showed that not only is there a lack of IFN- $\gamma$  signaling induction, but that the response *via* this pathway is downregulated as a whole (Figure 2D). At the individual gene level, a clear example that illustrates this situation is interferon gamma inducible protein 16 (*IFI16*), a DNA sensor previously shown to inhibit HBV cccDNA transcriptional activity (Yang et al., 2020). Indeed, HBV stimulation induced the downregulation of *IFI16* in human pDCs, which is markedly different from its upregulation in macaque pDCs (Figure 2E). Furthermore, we wanted to explore if the impairment of *IFI16* could be observed *in vivo* at later stages of the disease. Therefore, we analyzed a recently available scRNA-seq PBMC dataset (Zhang et al., 2023), obtained from healthy controls (HC,  $n=6$ ) or individuals at different stages of the disease, including immune tolerant (IT,  $n=6$ ), immune active (IA,  $n=5$ ), acute recovery (AR,  $n=3$ ) and chronic recovery (CR,  $n=6$ ) (Figure 2F, Supplementary Figure 2A). In this cohort, serum levels of HBsAg seem to be inversely associated with the expression of *IFI16* in the pDC population (Figure 2G). These results suggest that repression of *IFI16* takes place early during infection, showing the lowest levels at disease phases characterized by high viral load and progressively increasing with HBsAg loss. A similar repression was observed for additional components of the IFN- $\gamma$  signaling pathway, such as N-Myc and STAT interactor (*NMI*) and interferon regulatory factor 2 (*IRF2*) (Supplementary Figure 2B).

## Discussion

In the present study, we aimed to characterize the gene expression changes taking place early after exposure to HBV in the peripheral immune compartment (Figure 1A), as these events represent the starting point for the development of more complex intra- and intercellular immune responses (Netea et al., 2019). Moreover, our comparison between human and macaque immune populations provides a global view of the common and divergent innate responses between both species (Figure 1D). Thus, representing a useful resource to improve our understanding of HBV animal models and the identification of pathways to activate antiviral immune responses and viral clearance.


The initial examination of transcriptomic profiles from human and macaque immune populations seems to indicate that macaque PBMCs present a stronger immune response to the contact with HBV particles, as compared to human PBMCs. This may indicate that macaques are more prone to mount immune responses to HBV





infection. Indeed, we describe how macaque PBMCs exposed to HBV secrete IFN- $\gamma$  and TNF- $\alpha$ , while human PBMCs show only an increased secretion of IL-10 (Figures 2A–C). This is a relevant observation, as it has recently been described that distinct T cell populations can be identified in HBV-infected patients based on their TNF- $\alpha$ /IFN- $\gamma$  profile. In particular, successful differentiation of TNF- $\alpha$ -producing T cells into IFN- $\gamma$ -producing T cells is associated with HBV clearance (Wang et al., 2020). Moreover, we identified the DNA sensor *IFI16* as an IFN pathway component that is downregulated in human pDCs exposed to HBV *ex vivo*. Interestingly, analysis of publicly available transcriptomic data

from patients presenting a natural HBV infection with long duration showed that *IFI16* expression levels parallel HBsAg loss (Figure 2G). This is in line with previous reports describing how an increase in *IFI16* expression following peg-IFN treatment was associated with hepatitis B e antigen (HBeAg) seroconversion in CHB patients (Lu et al., 2021). Considering that *IFI16* levels increase following HBV clearance but do not seem to completely return to basal levels, it would be interesting to explore its potential epigenetic alteration. Indeed, this has been observed for components of the IFN- $\gamma$  pathway in response to HBV infection (Lim et al., 2018).



**FIGURE 2** *IFI16* expression is impaired in pDCs exposed to HBV *ex vivo* and persists in HBV-infected patients with long duration. (A–C) Interferon gamma (IFN- $\gamma$ ), tumor necrosis factor alpha (TNF- $\alpha$ ) and interleukin 10 (IL-10) levels in the supernatant of human and macaque PBMCs exposed *ex vivo* to HBV (Wilcoxon matched-pairs test). (D) GSEA showing a significant negative enrichment of IFN pathways in human pDCs exposed to HBV, in spite of an increased activity of pro-inflammatory MAPK signaling (FDR < 0.05). (E) Expression of *IFI16* is significantly downregulated in human pDCs and upregulated in macaque pDCs exposed to HBV *ex vivo* (FDR < 0.05, Wald test). (F) scRNA-seq data analysis depicting the multiple immune cell populations (left) identified in PBMCs from patients ( $n=23$ ) at different phases of natural HBV infection with long duration (right), including immune tolerant (IT), immune active (IA), acute recovery (AR), chronic resolved (CR) and HBV-free healthy controls (HC) (GSE182159). (G) HBsAg serum levels (top) are inversely associated with the expression of *IFI16* in pDCs (bottom) according to disease phase.

In summary, our dataset serves as a valuable resource to gain a deeper understanding of immune responses taking place during HBV infection. This and similar studies could prove useful for the identification of potential targets against HBV.

### Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE223073>.

### Ethics statement

The studies involving humans were approved by French National Blood Service (Etablissement Français du Sang, Lyon, France). The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from French National Blood Service (Etablissement Français du Sang, Lyon, France). Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements. The animal study was approved by international guidelines (CITES n°

FR1503100944-I). The study was conducted in accordance with the local legislation and institutional requirements.

## Author contributions

Conceptualization: IC; Methodology: IC and UH; Data acquisition: SP, AT, FP, CC, AD, EC, LP, FR, AS, and CB; Formal analysis: AR, XG, JB, TT, CC, BV, UH, and IC; Writing – original draft: AR; Writing – review & editing: XG, BV, BT, PR, FZ, UH, and IC. All authors contributed to the article and approved the submitted version.

## Funding

This research project has received funding from the French Government through the Investissement d'Avenir program (grant n°ANR-10-AIRT-03) in a joint program with the Janssen company.

## Acknowledgments

We thank Dr. C. Caux and Dr. Y. Grinberg from Beyer for their scientific discussions, as well as Dr. H. Horton.

## References

- Bertoletti, A., and Kennedy, P. T. F. (2019). HBV antiviral immunity: not all CD8 T cells are born equal. *Gut* 68, 770–773. doi: 10.1136/gutjnl-2018-317959
- Biswas, S., Rust, L. N., Wettengel, J. M., Yusova, S., Fischer, M., Carson, J. N., et al. (2022). Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunity. *Nat. Commun.* 13, 2995. doi: 10.1038/s41467-022-30593-0
- Burwitz, B. J., Wettengel, J. M., Mück-Häusel, M. A., Ringelhan, M., Ko, C., Festag, M. M., et al. (2017). Hepatocytic expression of human sodium-taurocholate cotransporting polypeptide enables hepatitis B virus infection of macaques. *Nat. Commun.* 8, 2146. doi: 10.1038/s41467-017-01953-y
- Dupinay, T., Gheit, T., Roques, P., Cova, L., Chevallier-Queyron, P., Tasahsu, S., et al. (2013). Discovery of naturally occurring transmissible chronic hepatitis B virus infection among *Macaca fascicularis* from Mauritius Island. *Hepatology* 58, 1610–1620. doi: 10.1002/hep.26428
- EASL (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J. Hepatol.* 67, 370–398. doi: 10.1016/j.jhep.2017.03.021
- Estes, J. D., Wong, S. W., and Brechley, J. M. (2018). Nonhuman primate models of human viral infections. *Nat. Rev. Immunol.* 18, 390–404. doi: 10.1038/s41577-018-0005-7
- Faure-Dupuy, S., Durantel, D., and Lucifora, J. (2018). Liver macrophages: Friend or foe during hepatitis B infection? *Liver Int.* 38, 1718–1729. doi: 10.1111/liv.13884
- Hong, M., and Bertoletti, A. (2017). Tolerance and immunity to pathogens in early life: insights from HBV infection. *Semin. Immunopathol.* 39, 643–652. doi: 10.1007/s00281-017-0641-1
- Iannacone, M., and Guidotti, L. G. (2022). Immunobiology and pathogenesis of hepatitis B virus infection. *Nat. Rev. Immunol.* 22, 19–32. doi: 10.1038/s41577-021-00549-4
- Li, H., Zhai, N., Wang, Z., Song, H., Yang, Y., Cui, A., et al. (2018). Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection. *Gut* 67, 2035–2044. doi: 10.1136/gutjnl-2017-314098
- Lim, S. G., Baumert, T. F., Boni, C., Gane, E., Levrero, M., Lok, A. S., et al. (2023). The scientific basis of combination therapy for chronic hepatitis B functional cure. *Nat. Rev. Gastroenterol. Hepatol.* 20, 238–253. doi: 10.1038/s41575-022-00724-5
- Lim, K.-H., Park, E.-S., Kim, D. H., Cho, K. C., Kim, K. P., Park, Y. K., et al. (2018). Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5'-UTR of TRIM22. *Gut* 67, 166–178. doi: 10.1136/gutjnl-2016-312742
- Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550. doi: 10.1186/s13059-014-0550-8
- Lu, Y.-Q., Wu, J., Wu, X.-J., Ma, H., Ma, Y.-X., Zhang, R., et al. (2021). Interferon gamma-inducible protein 16 of peripheral blood mononuclear cells may sense hepatitis

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcimb.2023.1248782/full#supplementary-material>

B virus infection and regulate the antiviral immunity. *Front. Cell Infect. Microbiol.* 11. doi: 10.3389/fcimb.2021.790036

Maini, M. K., and Burton, A. R. (2019). Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. *Nat. Rev. Gastroenterol. Hepatol.* 16, 662–675. doi: 10.1038/s41575-019-0196-9

Martinez, M. G., Boyd, A., Combe, E., Testoni, B., and Zoulim, F. (2021). Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections. *J. Hepatol.* 75, 706–717. doi: 10.1016/j.jhep.2021.05.013

Netea, M. G., Schlitzer, A., Placek, K., Joosten, L. A. B., and Schultze, J. L. (2019). Innate and adaptive immune memory: an evolutionary continuum in the host's response to pathogens. *Cell Host Microbe* 25, 13–26. doi: 10.1016/j.chom.2018.12.006

Op den Brouw, M. L., Binda, R. S., van Roosmalen, M. H., Protzer, U., Janssen, H. L. A., van der Molen, R. G., et al. (2009). Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. *Immunology* 126, 280–289. doi: 10.1111/j.1365-2567.2008.02896.x

Ortega-Prieto, A. M., Cherry, C., Gunn, H., and Dorner, M. (2019). *In vivo* model systems for hepatitis B virus research. *ACS Infect. Dis.* 5, 688–702. doi: 10.1021/acscinfed.8b00223

Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., and Kingsford, C. (2017). Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* 14, 417–419. doi: 10.1038/nmeth.4197

Satija, R., Farrell, J. A., Gennert, D., Schier, A. F., and Regev, A. (2015). Spatial reconstruction of single-cell gene expression data. *Nat. Biotechnol.* 33, 495–502. doi: 10.1038/nbt.3192

Tout, I., Gomes, M., Ainouze, M., Marotel, M., Pecoul, T., Durantel, D., et al. (2018). Hepatitis B virus blocks the CRE/CREB complex and prevents TLR9 transcription and function in human B cells. *J. Immunol.* 201, 2331–2344. doi: 10.4049/jimmunol.1701726

Turelli, P., Mangeat, B., Jost, S., Vianin, S., and Trono, D. (2004). Inhibition of hepatitis B virus replication by APOBEC3G. *Science* 303, 1829. doi: 10.1126/science.1092066

Wang, H., Luo, H., Wan, X., Fu, X., Mao, Q., Xiang, X., et al. (2020). TNF- $\alpha$ /IFN- $\gamma$  profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. *J. Hepatol.* 72, 45–56. doi: 10.1016/j.jhep.2019.08.024

Yang, Y., Zhao, X., Wang, Z., Shu, W., Li, L., Li, Y., et al. (2020). Nuclear sensor interferon-inducible protein 16 inhibits the function of hepatitis B virus covalently closed circular DNA by integrating innate immune activation and epigenetic suppression. *Hepatology* 71, 1154–1169. doi: 10.1002/hep.30897

Yu, C.-R., Mahdi, R. M., Ebong, S., Vistica, B. P., Gery, I., and Egwuagu, C. E. (2003). Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. *J. Biol. Chem.* 278, 29752–29759. doi: 10.1074/jbc.M300489200

Yuen, M.-F., Chen, D.-S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., et al. (2018). Hepatitis B virus infection. *Nat. Rev. Dis. Primers* 4, 18035. doi: 10.1038/nrdp.2018.35

Zhang, C., Li, J., Cheng, Y., Meng, F., Song, J.-W., Fan, X., et al. (2023). Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to

disease phases in HBV-infected patients. *Gut* 72, 153–167. doi: 10.1136/gutjnl-2021-325915

Zhao, K., Liu, A., and Xia, Y. (2020). Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery. *Innovation* 1, 100034. doi: 10.1016/j.xinn.2020.100034